In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Nuvectra closes $64.9mm FOPO

Executive Summary

Nuvectra Corp. (neuromodulation devices) netted $64.9mm in a public offering of 3.2mm shares (including the overallotment) at $21.25. The company will use the proceeds to expand product development and commercialization. Nuvectra is awaiting CE Mark and PMA approval for its Virtis sacral nerve stimulation (SNS) device for urinary incontinence and overactive bladder. In July, both EU and US agencies informed Nuvectra that additional clinical study data would be required before recommending approval, but the company still anticipates product launches by the end of the year (EU) and during 1H 2019 (US).
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies